Catégorie : Essais Cliniques

Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder : Open-Label Single-Arm Pilot Study, Maud Rothärmel et al., 2022

Efficacy and Safety of Intranasal Esketamine in Patients With Treatment-Resistant Depression and Comorbid Chronic Post-traumatic Stress Disorder : Open-Label Single-Arm Pilot Study Maud Rothärmel, Cherifa Benosman, Wissam El-Hage, Caroline Berjamin, Diane Ribayrol, Olivier Guillin, Raphaël Gaillard, Lucie Berkovitch and Virginie Moulier Frontiers in Psychiatry, 2022 | Volume 13 | Article 865466 doi : 10.3389/fpsyt.2022.865466   Abstract Introduction: Major depressive disorder (MDD) is more likely to resist to usual treatment when it is associated with post-traumatic stress disorder (PTSD). Capitalizing on the effect of ketamine in both treatment-resistant depression (TRD) and PTSD, we conducted a study in order to assess the efficacy of intranasal (IN) Esketamine in [...]

Lire la suite

Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol. Pharmacokinetics and Pharmacodynamics in Healthy Adults : A Randomized Clinical Trial, C. Austin Zamarripa et al., 2023

Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol. Pharmacokinetics and Pharmacodynamics in Healthy Adults : A Randomized Clinical Trial C. Austin Zamarripa, PhD; Tory R. Spindle, PhD; Renuka Surujunarain; Elise M. Weerts, PhD; Sumit Bansal, PhD; Jashvant D. Unadkat, PhD; Mary F. Paine, PhD; Ryan Vandrey, PhD Jama Network Open, 2023, 6, (2), e2254752, 1-15. doi : 10.1001/jamanetworkopen.2022.54752 Key Points Question : Are there acute pharmacokinetic or pharmacodynamic differences between oral ingestion of a Δ9-tetrahydrocannabinol (Δ9-THC)- dominant cannabis extract compared with a cannabidiol (CBD)-dominant extract at the same Δ9-THC dose (20 mg) in healthy adults who use cannabis infrequently? Findings : In this randomized clinical trial including 18 [...]

Lire la suite

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects, Aviva Breuer et al., 2016

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects Aviva Breuer, Christeene G. Haj, Manoela V. Fogaça, Felipe V. Gomes, Nicole Rodrigues Silva, João Francisco Pedrazzi, Elaine A. Del Bel, Jaime C. Hallak, José A. Crippa, Antonio W. Zuardi, Raphael Mechoulam, Francisco S. Guimarães PLOS One, 2016, 11, (7), e0158779, 1-19. Doi : 10.1371/journal.pone.0158779   Abstract Cannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharma- cological assays, including mice tests for anxiety, obsessive-compulsive disorder, depres- sion and schizophrenia. In human [...]

Lire la suite

Editorial : Psychological Aspects of Cannabis Use and Cannabis Use Disorder, Daniel Feingold et al., 2021

Editorial: Psychological Aspects of Cannabis Use and Cannabis Use Disorder Daniel Feingold, Eva Hoch, Aviv Weinstein and Wayne Hall Frontiers in Psychiatry, 2021, Volume 12 | Article 789197 doi : 10.3389/fpsyt.2021.789197   Editorial on the Research Topic : Psychological Aspects of Cannabis Use and Cannabis Use Disorder   Keywords : cannabis, marijuana, cannabis use disorder, psychology, cognition, emotion An increasing global prevalence of cannabis use has produced increased treatment seeking for Cannabis Use Disorder (CUD) and an increased research effort to identify factors associated with initiation of cannabis use, transitions to regular cannabis use and the onset of CUD (1, 2). The majority of empirical studies focus on biological and [...]

Lire la suite

Attitudes Toward the Use of Medical Cannabis and the Perceived Efficacy, Side-effects and Risks : A Survey of Patients, Nurses and Physicians, Neta HaGani et al., 2021

Attitudes Toward the Use of Medical Cannabis and the Perceived Efficacy, Side-effects and Risks : A Survey of Patients, Nurses and Physicians Neta HaGani, Sharon Sznitman, Michael Dor, Gil Bar-Sela, Dana Oren, Lilia Margolis-Dorfman, Itay Goor-Aryeh & Manfred S. Green Journal of Psychoactive Drugs, 2021, 1-10. Doi : 10.1080/02791072.2021.2009598   ABSTRACT Gaps between physician and patient perceptions may lead to misunderstandings and mismanage of treatment. There are sparse data about the differences in opinions toward medical cannabis (MC) between patients and health professionals. The aim of this study was to examine the attitudes toward MC, its perceived efficacy, side effects and risk of dependency, among patients, [...]

Lire la suite

Posttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study, Sharon R. Sznitman et al., 2022

Posttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study Sharon R. Sznitman, David Meiri, Ben H. Amit, Dennis Rosenberg, Talya Greene Journal of Anxiety Disorders, 2022, 92, 102632 Doi : 10.1016/j.janxdis.2022.102632 Abstract Despite increasing use of Medical Cannabis (MC) among posttraumatic stress disorder(PTSD) patients, research is lacking on how MC treatment relates to PTSD symptomatology, in particular sleep disturbances. This study examines the time gap between MC use and sleep onset and its association with (1) number of awakenings throughout the night, (2) early awakenings, (3) nightmares. Each morning over a two week period, 77 licensed MC patients suffering from PTSD reported [...]

Lire la suite

The Rapid Rise in Investment in Psychedelics— Cart Before the Horse, Joshua PHELPS et al., 2022

The Rapid Rise in Investment in Psychedelics— Cart Before the Horse Joshua PHELPS, Ravi N. SHAH, Jeffrey A. LIEBERMAN, JAMA Psychiatry, 2022, 79, (3), 189-190. Doi : 10.1001/jamapsychiatry.2021.3972   Anticipating a renaissance, many psychedelic medicine companies have conducted initial public offerings, where in private companies first issue news hares of stock for sale to the public, making the companies publicly traded entities.1 As of this writing, there are more than 50 publicly traded companies related to the development or administration of psychedelic like drugs in the US, with at least 3 valued at more than $1 billion. The market for psychedelic substances is projected to [...]

Lire la suite

Endocannabinoid System as Therapeutic Target of PTSD : A Systematic Review, Luca Steardo, Jr. et al., 2021

Endocannabinoid System as Therapeutic Target of PTSD : A Systematic Review Luca Steardo, Jr., Elvira Anna Carbone, Giulia Menculini, Patrizia Moretti, Luca Steardo and Alfonso Tortorella Life, 2021, 11, 214. Doi : 10.3390/life11030214 Abstract : Post-Traumatic Stress Disorder (PTSD) is a complex disorder involving dysregulation of stress-related hormones and neurotransmitter systems. Research focused on the endocannabinoid system (eCBS) for anxiety and stress regulation, cognitive and emotional responses modulation and aversive memories extinction, leading to the hypothesis that it could represent a possible alternative treatment target for PTSD. In this systematic review, we summarize evidence about the efficacy and safety of medicinal cannabidiol (CBD), D9-tetrahydrocannabinol (D9-THC), and [...]

Lire la suite

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review, Laura Orsolini et al., 2019

Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review Laura Orsolini, Stefania Chiappini, Umberto Volpe, Domenico De Berardis, Roberto Latini, Gabriele Duccio Papanti  and John Martin Corkery Medicina, 2019, 55, 525, 1-14 doi : 10.3390/medicina55090525 www.mdpi.com/journal/medicina Abstract : Background and Objectives : Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives [...]

Lire la suite

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique, Dr Christian SUEUR, GRECC, version 3-5, mars 2022

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, GRECC, version 3-5 Dr Christian SUEUR, mars 2022 112 pages       Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1]   En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout en précisant [...]

Lire la suite